Orphan Drugs & Rare Diseases 2013

Topics

• How research & development and market access costs must be controlled
• Unique `Big Pharma Spotlight` sessions to understand current pipelines
• Case studies of new molecules in clinical trials
• Optimal targeting of a new drug by reviewing it with patient groups to engage rare diseases
• Current funding options; including financial and economic reimbursement for the clinical development of drugs

Who should Attend

Attendees from pharma and biotech companies, CROs, regulatory bodies and legal experts involved in:

• Legislation and Policy Advice
• Intellectual Property
• Licensing
• Business Development
• APIs
• Manufacturing
• Drug and Safety Assessment
• Bioequivalence
• Regulatory Affairs
• Market Strategy